The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) hit a new 52-week high and has $34.49 target or 3.00% above today’s $33.49 share price. The 9 months bullish chart indicates low risk for the $1.22 billion company. The 1-year high was reported on Nov, 25 by Barchart.com. If the $34.49 price target is reached, the company will be worth $36.60M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 37,541 shares traded hands. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has risen 14.67% since April 22, 2016 and is uptrending. It has outperformed by 9.26% the S&P500.
Analysts await AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) to report earnings on February, 15. They expect $0.27 earnings per share, up 35.00% or $0.07 from last year’s $0.2 per share. AMAG’s profit will be $9.84M for 31.01 P/E if the $0.27 EPS becomes a reality. After $0.43 actual earnings per share reported by AMAG Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -37.21% negative EPS growth.
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Ratings Coverage
Out of 6 analysts covering AMAG Pharmaceuticals (NASDAQ:AMAG), 4 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 67% are positive. AMAG Pharmaceuticals has been the topic of 16 analyst reports since August 18, 2015 according to StockzIntelligence Inc. The rating was maintained by Leerink Swann with “Outperform” on Wednesday, May 4. On Thursday, November 19 the stock rating was maintained by Deutsche Bank with “Hold”. Barclays Capital initiated the stock with “Equal-Weight” rating in Thursday, January 21 report. The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) earned “Market Perform” rating by Raymond James on Wednesday, May 4. The rating was initiated by Raymond James with “Outperform” on Tuesday, September 1. The firm has “Strong-Buy” rating by Zacks given on Wednesday, August 19. The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) earned “Hold” rating by Deutsche Bank on Wednesday, November 4. The stock has “Hold” rating given by Deutsche Bank on Thursday, September 3. The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) earned “Buy” rating by Needham on Thursday, October 27. As per Thursday, August 11, the company rating was maintained by Jefferies.
According to Zacks Investment Research, “AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. Ferumoxytol, the company’s key product candidate, is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease patients.CombidexÂ®, the company’s other product under development, is an investigational functional molecular imaging agent consisting of iron oxide nanoparticles for use in conjunction with magnetic resonance imaging to aid in the differentiation of cancerous from normal lymph nodes. In March 2005, the company received an approvable letter from the FDA with respect to Combidex, subject to certain conditions.”
Insitutional Activity: The institutional sentiment increased to 1.07 in Q2 2016. Its up 0.24, from 0.83 in 2016Q1. The ratio improved, as 33 funds sold all AMAG Pharmaceuticals, Inc. shares owned while 51 reduced positions. 15 funds bought stakes while 55 increased positions. They now own 42.73 million shares or 1.35% more from 42.16 million shares in 2016Q1.
Regions Fincl Corporation, a Alabama-based fund reported 48,337 shares. Sector Pension Inv Board has 24,700 shares for 0.01% of their US portfolio. Quantbot Techs Lp, a New York-based fund reported 1,214 shares. Blackrock Japan Co reported 323 shares or 0% of all its holdings. Blackrock Fund has invested 0.02% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Credit Cap Investments Ltd Liability holds 1.01% or 713,126 shares in its portfolio. Dupont Capital Management Corp owns 33,838 shares or 0.02% of their US portfolio. Moreover, Ironwood Mngmt Ltd has 0.82% invested in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) for 45,635 shares. Moreover, Ashford Cap Management has 0.8% invested in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) for 149,050 shares. Clark Estates Incorporated Ny last reported 0.42% of its portfolio in the stock. Bnp Paribas Arbitrage, a New York-based fund reported 106,956 shares. Thrivent Finance For Lutherans accumulated 16,940 shares or 0% of the stock. Whittier has 2,292 shares for 0% of their US portfolio. Signalpoint Asset Mngmt Limited Com last reported 0.2% of its portfolio in the stock. Jane Street Group Inc Ltd Limited Liability Company reported 11,955 shares or 0% of all its holdings.
Insider Transactions: Since October 20, 2016, the stock had 0 insider buys, and 1 insider sale for $122,462 net activity. Krop Julie sold $122,462 worth of stock or 4,938 shares.
AMAG Company Profile
AMAG Pharmaceuticals, Inc., incorporated on November 9, 1981, is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of services and products for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. The Firm has a portfolio of services and products with a focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol) for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.